DREAMM-7 Design, Efficacy, and Safety

The panel reviews theDREAMM-7 study, which compared belantamab mafodotin with bortezomib and dexamethasone against daratumumab with bortezomib and dexamethasone.The primary end point was progression-free survival (PFS), with secondary end points including response rate, minimal residual disease, overall survival (OS), and quality of life.Patients had at least 1 prior line of therapy, active progression of multiple myeloma, and were not daratumumab refractory. The faculty describe very impressive results, with every tested secondary end point, including OS, favoring the antibody-drug conjugate (ADC).On safety, the drug affects cornealstem cells,producing expected,temporary arrest with ocular toxicity occurring typically after the first 2 doses, managed by delaying doses. Other adverse effects include neutropenia and thrombocytopenia. The panel contrasts grade 3 infection rates of up to 40% to 50% with bispecific antibodies against less than 10% with the ADC.